Financials
Financial year 2025
Kesters Pharma Invest from Houthalen-Helchteren, company number BE1025025031, closed financial year 2025 with a result of € 36,924 after tax. For that financial year Kesters Pharma Invest recorded a gross margin of € 51,798 and equity of € 39,624. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 9, 2026.
€ 39,624
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 36,924
Profit after tax over the fiscal year.
€ 29,545
Cash and bank balances on the last day of the fiscal year.
€ 800 paid out
2 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 600
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 412,543
€ 52,491 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 4
Supplier invoices still open on the last day of the fiscal year.
€ 9,878
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to Kesters Pharma Invest?
What happened at Kesters Pharma Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 36,924. Source: NBB ↗
- New establishment in Houthalen-Helchteren. KBO
- Kevin Kesters became a director. NBB
- Start of the company according to the CBE. KBO
In short
Paid € 9,262 in corporate taxes since 2025.
Paid out € 800 in dividends to the owners in total.
A new publication or filing at Kesters Pharma Invest? We notify you, reason included.
Follow Kesters Pharma InvestDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Kesters Pharma Invest is Kevin Kesters.
Directors
According to the 2025 annual accounts
Kevin Kesters
Bestuurder
since 2025
Establishments
Establishment units
Physical locations of this company
Kazernelaan 22 box 2-1
3530 Houthalen-Helchteren
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1025.025.031
- VAT number
- BE 1025.025.031
- Registered office
- Kazernelaan 22 bus 2-1, 3530 Houthalen-Helchteren
- Names & denominations
- Kesters Pharma Invest
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 July 2025
- Peppol
- Active · Active since 25 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Overige zakelijke dienstverlening, neg